Let‑7b binding site polymorphism in the B‑cell lymphoma‑extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma

Ma,Jin; Guo,Rui; Wang,Ting; Pan,Xia; Lei,Xiaoyong

doi:10.3892/mmr.2014.2692

Let‑7b binding site polymorphism in the B‑cell lymphoma‑extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma

Authors:
- Jin Ma
- Rui Guo
- Ting Wang
- Xia Pan
- Xiaoyong Lei
View Affiliations

Affiliations: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: October 17, 2014 https://doi.org/10.3892/mmr.2014.2692
Pages: 677-681

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B‑cell lymphoma‑extra large (Bcl‑xl) is an anti‑apoptotic member of the B‑cell lymphoma 2 (Bcl‑2) family that is often found to be overexpressed in human hepatocellular carcinoma (HCC), therefore conferring a survival advantage to tumor cells. microRNA (miRNA) let‑7b is downregulated in HCC and its expression correlates with multidrug resistance. Using computational programs, it was predicted that the 3' untranslated region (UTR) of the Bcl‑xl gene contains a potential miRNA binding site for let‑7b, and that a single nucleotide polymorphism (SNP) site rs3208684 (A or C allele) resides within this binding site. Luciferase assays and western blot analysis demonstrated that let‑7b targeted Bcl‑xl gene expression and negatively regulated the amount of Bcl‑xl protein. SNP rs3208684 (A>C) variation enhanced the expression of Bcl‑xl by disrupting the binding of let‑7b to the 3'UTR of Bcl‑xl. The effects of the two polymorphic variants on chemotherapeutic drug sensitivity were determined by cell counting kit 8 assays. Overexpression of the Bcl‑xl mutated (C) allele in BEL‑7402 HCC cells significantly decreased fluorouracil (5‑FU) sensitivity, as compared with mock transfection and overexpression of the wild‑type allele. From this, it was concluded that let‑7b increased 5‑FU sensitivity by repressing Bcl‑xl expression in HCC cells. These results suggest that SNP (rs3208684) may be a potential marker for personalized treatment.

View Figures

View References

1	Borel F, Han R, Visser A, et al; Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology. 55:821–832. 2012.
2	van Oosterwijk JG, Herpers B, Meijer D, et al: Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol. 23:1617–1626. 2012.PubMed/NCBI
3	Zhu W, Xu H, Zhu D, et al: miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zhu W, Zhu D, Lu S, et al: miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J and Armeanu-Ebinger S: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer. 55:1089–1095. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C and Schuler M: Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 121:2387–2394. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mallick S, Patil R, Gyanchandani R, Pawar S, et al: Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1. J Pathol. 217:398–407. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ma B, Zhang H, Wang J, Zhang B, Xu X and Cheng B: HIV-1 viral protein R (Vpr) induction of apoptosis and cell cycle arrest in multidrug-resistant colorectal cancer cells. Oncol Rep. 28:358–364. 2012.PubMed/NCBI
9	Di Leva G and Croce CM: Roles of small RNAs in tumor formation. Trends Mol Med. 16:257–267. 2010.PubMed/NCBI
10	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Slaby O, Bienertova-Vasku J, Svoboda M and Vyzula R: Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med. 16:8–21. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yin J, Tang HF, Xiang Q, Yu J, Yang XY, Hu N and Lei XY: MiR-122 increases sensitivity of drug-resistant BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2 family proteins. Pharmazie. 66:975–981. 2011.PubMed/NCBI
13	Yang X, Yin J, Yu J, et al: miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep. 27:250–257. 2012.PubMed/NCBI
14	Hou J, Lin L, Zhou W, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhang J, Cheng C, He CL, Zhou YJ and Cao Y: The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. Cancer Invest. 26:456–463. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
18	Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by let-7 microRNA family. Cell. 120:635–647. 2005. View Article : Google Scholar
19	Sampson VB, Rong NH, Han J, et al: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 67:9762–9770. 2007. View Article : Google Scholar : PubMed/NCBI
20	Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
21	Johnson CD, Esquela-Kerscher A, Stefani G, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
22	Büssing I, Slack FJ and Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trend Mol Med. 14:400–409. 2008.
23	Shimizu S, Takehara T, Hikita H, et al: The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 52:698–704. 2010. View Article : Google Scholar : PubMed/NCBI
24	Qin B, Xiao B, Liang D, Li Y, Jiang T and Yang H: MicroRNA let-7c inhibits Bcl-xl expression and regulates ox-LDL-induced endothelial apoptosis. BMB Rep. 45:464–469. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hummel R, Hussey DJ and Haier J: MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
26	Nicoloso MS, Sun H, Spizzo R, et al: Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 70:2789–2798. 2010. View Article : Google Scholar : PubMed/NCBI
27	Mishra PJ and Bertino JR: MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 10:399–416. 2009. View Article : Google Scholar : PubMed/NCBI
28	Smits KM, Paranjape T, Nallur S, et al: A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 17:7723–7731. 2011.
29	Zhang L, Liu Y, Song F, et al: Functional SNP in the microRNA-367 binding site in the 3′UTR of the calcium channel ryanodine receptor gene3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA. 108:13653–13658. 2011.PubMed/NCBI
30	Pharoah PD, Palmieri RT, Ramus SJ, et al: The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 17:3742–3750. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the 3′ untranslated region of the AP-2α gene is associated with cisplatin resistance. PLoS One. 6:e290432011.PubMed/NCBI
32	Peddaboina C, Jupiter D, Fletcher S, et al: The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer. 12:5412012. View Article : Google Scholar : PubMed/NCBI
33	Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP and Bansal S: The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem. 287:32875–32880. 2012.PubMed/NCBI